Lombard Odier Asset Management Switzerland SA Increases Stock Holdings in Eli Lilly and Company $LLY

Key Points

• Lombard Odier Asset Management Switzerland SA increased its Eli Lilly stake by 14% in the first quarter, buying 4,423 additional shares to bring its total to 36,080 shares worth about $33.2 million.
• Eli Lilly reported better-than-expected quarterly results, with EPS of $8.55 and revenue of $19.8 billion, both beating analyst estimates and marking 55.5% year-over-year revenue growth.
• The company’s pipeline and outlook remain in focus, as Lilly reported strong Phase 3 results for its obesity drug retatrutide and plans to file for FDA approval in Q1 2027, though it also faces legal pressure from Novo Nordisk over its obesity and diabetes ads.

Lombard Odier Asset Management Switzerland SA raised its position in Eli Lilly and Company (NYSE:LLY - Free Report) by 14.0% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 36,080 shares of the company's stock after acquiring an additional 4,423 shares during the quarter. Eli Lilly and Company makes up approximately 1.3% of Lombard Odier Asset Management Switzerland SA's portfolio, making the stock its 11th biggest position. Lombard Odier Asset Management Switzerland SA's holdings in Eli Lilly and Company were worth $33,185,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Maryland Capital Advisors Inc. acquired a new position in shares of Eli Lilly and Company in the fourth quarter valued at approximately $25,000. Osbon Capital Management LLC acquired a new stake in Eli Lilly and Company during the 4th quarter worth approximately $25,000. Basso Capital Management L.P. purchased a new position in Eli Lilly and Company in the 4th quarter valued at approximately $30,000. Maseco LLP grew its stake in shares of Eli Lilly and Company by 466.7% in the first quarter. Maseco LLP now owns 34 shares of the company's stock worth $31,000 after acquiring an additional 28 shares in the last quarter. Finally, E Fund Management Hong Kong Co. Ltd. grew its stake in shares of Eli Lilly and Company by 342.9% in the fourth quarter. E Fund Management Hong Kong Co. Ltd. now owns 31 shares of the company's stock worth $32,000 after acquiring an additional 24 shares in the last quarter. 82.53% of the stock is currently owned by hedge funds and other institutional investors.

Eli Lilly and Company Stock Performance

NYSE:LLY opened at $1,196.18 on Friday. Eli Lilly and Company has a 12 month low of $623.78 and a 12 month high of $1,249.45. The company has a debt-to-equity ratio of 1.26, a current ratio of 1.50 and a quick ratio of 1.10. The firm has a market capitalization of $1.13 trillion, a PE ratio of 42.49, a price-to-earnings-growth ratio of 1.51 and a beta of 0.51. The business's fifty day moving average price is $1,136.56 and its 200 day moving average price is $1,040.15.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last announced its quarterly earnings results on Thursday, April 30th. The company reported $8.55 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $6.97 by $1.58. The company had revenue of $19.80 billion during the quarter, compared to the consensus estimate of $17.82 billion. Eli Lilly and Company had a return on equity of 105.77% and a net margin of 34.98%.Eli Lilly and Company's revenue for the quarter was up 55.5% on a year-over-year basis. During the same period in the previous year, the business earned $3.34 EPS. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. On average, sell-side analysts anticipate that Eli Lilly and Company will post 35.03 earnings per share for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Thursday, September 10th. Investors of record on Friday, August 14th will be paid a dividend of $1.73 per share. The ex-dividend date is Friday, August 14th. This represents a $6.92 annualized dividend and a yield of 0.6%. Eli Lilly and Company's payout ratio is presently 24.58%.

Key Headlines Impacting Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Eli Lilly reported strong late-stage results for retatrutide, its next-generation obesity drug, in two Phase 3 trials. The drug met its primary endpoint and produced substantial weight loss and A1C improvement, reinforcing expectations for a major future growth franchise. Article Title
• Positive Sentiment: The company said it now plans to file for FDA approval of retatrutide in Q1 2027, keeping the drug on a path toward commercialization and supporting the long-term growth outlook for LLY. Article Title
• Positive Sentiment: A Lilly-backed biotech, Scribe Therapeutics, priced an upsized IPO with strong demand, highlighting continued investor appetite for Lilly-associated pipeline assets and partnerships. Article Title
• Neutral Sentiment: Healthcare stocks were broadly higher late Friday, which may be lending general support to Eli Lilly’s shares. Article Title
• Negative Sentiment: Novo Nordisk is seeking a preliminary injunction to block Lilly’s weight-loss and diabetes ads, accusing the company of using outdated data and misleading comparisons versus Wegovy and Ozempic. That raises legal and regulatory risk for Eli Lilly, even if the impact is likely more headline-driven than fundamental for now. Article Title

Analyst Ratings Changes

A number of research analysts recently issued reports on the company. Sanford C. Bernstein lifted their target price on Eli Lilly and Company from $1,300.00 to $1,385.00 and gave the company an "outperform" rating in a report on Tuesday, July 14th. Leerink Partners increased their price target on Eli Lilly and Company from $1,119.00 to $1,232.00 and gave the company an "outperform" rating in a research report on Thursday, June 25th. Jefferies Financial Group lifted their price objective on Eli Lilly and Company from $1,330.00 to $1,350.00 and gave the company a "buy" rating in a research note on Tuesday, June 9th. Guggenheim boosted their price objective on Eli Lilly and Company from $1,235.00 to $1,273.00 and gave the stock a "buy" rating in a research report on Monday, July 13th. Finally, Citigroup upped their target price on shares of Eli Lilly and Company from $1,500.00 to $1,600.00 and gave the stock a "buy" rating in a research note on Wednesday, July 15th. Two research analysts have rated the stock with a Strong Buy rating, twenty-four have given a Buy rating, four have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average target price of $1,283.64.

About Eli Lilly and Company

Eli Lilly and Company NYSE: LLY is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.